Advancements in the management of pediatric inflammatory bowel disease.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-12-17 DOI:10.1080/17474124.2024.2444555

Jonathan E M O'Donnell, Thomas D Walters, Eric I Benchimol

{"title":"Advancements in the management of pediatric inflammatory bowel disease.","authors":"Jonathan E M O'Donnell, Thomas D Walters, Eric I Benchimol","doi":"10.1080/17474124.2024.2444555","DOIUrl":null,"url":null,"abstract":"Introduction: The management of pediatric inflammatorybowel disease (PIBD) has drastically changed in the last decade. The limitedavailability of new biologics or small molecule therapies, and concerns aboutdurability in children has necessitated the development of other advances inmanagement to optimize care.Areas covered: Thisreview covers guidance for management targets andadvances in optimizing biologic therapies, newmedical therapies, adjuvant therapies, precision medicine and mental healthconcerns in PIBD. This review focused on recent advances and was not intendedas a complete overview of the investigations and management of pediatricIBD.Expert opinion: Advancements includestandardization of treatment goals via a treat-to-target strategy, optimizinganti-TNF biologics through combination therapy or proactive drug monitoring,earlier initiation of treatment for Crohn's disease, the emergence of newbiologic/advanced therapies and a growing focus on adjuvant therapies targetingthe microbiome. Future progress relies on the inclusion of children/adolescentsin clinical trials to facilitate faster regulatory approval for pediatrictherapies and the integration of precision medicine and mental health screeningto improve patient care and outcomes.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2444555","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The management of pediatric inflammatorybowel disease (PIBD) has drastically changed in the last decade. The limitedavailability of new biologics or small molecule therapies, and concerns aboutdurability in children has necessitated the development of other advances inmanagement to optimize care.

Areas covered: Thisreview covers guidance for management targets andadvances in optimizing biologic therapies, newmedical therapies, adjuvant therapies, precision medicine and mental healthconcerns in PIBD. This review focused on recent advances and was not intendedas a complete overview of the investigations and management of pediatricIBD.

Expert opinion: Advancements includestandardization of treatment goals via a treat-to-target strategy, optimizinganti-TNF biologics through combination therapy or proactive drug monitoring,earlier initiation of treatment for Crohn's disease, the emergence of newbiologic/advanced therapies and a growing focus on adjuvant therapies targetingthe microbiome. Future progress relies on the inclusion of children/adolescentsin clinical trials to facilitate faster regulatory approval for pediatrictherapies and the integration of precision medicine and mental health screeningto improve patient care and outcomes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.